ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 17 Jul 2023
Last Updated on 01 Sep 2023
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended trastuzumab deruxtecan (T-DXd) for inclusion on the MOH List of Subsidised Drugs for treating human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma in patients who have received two or more prior therapies. The decision was based on the unfavourable cost-effectiveness of T-DXd at the price proposed by the company compared with chemotherapy. 


Clinical indication, subsidy class and MediShield Life claim limit for T-DXd are provided in the Annex.


Trastuzumab deruxtecan for treating HER2-positive advanced gastric cancer after two or more therapies (Published 1 Sep 23) PES Trastuzumab deruxtecan for previously treated HER2-positive advanced gastric cancer (Updated 1 Sep 23)